Status:
ACTIVE_NOT_RECRUITING
Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma
Lead Sponsor:
Intergroupe Francophone du Myelome
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-ho...
Detailed Description
To evaluate the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in Multiple Myeloma patients. 180 evaluable p...
Eligibility Criteria
Inclusion Criteria:
- Patient with Multiple Myeloma
- Patient starting new treatment line, whatever the line is, but with at least 3 induction cycles
- Urine monoclonal component ≥ 200mg/24h
Exclusion Criteria:
Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision
Key Trial Info
Start Date :
May 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05208086
Start Date
May 18 2022
End Date
May 1 2026
Last Update
April 13 2026
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Ch Annecy Genevois
Annecy, France
2
Centre Hospitalier Métropole de Savoie
Chambéry, France
3
CHU François Mitterand
Dijon, France
4
CH de Dunkerque
Dunkirk, France